A5012489616- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Integrated Circuits and Semiconductor Failure Analysis
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Cancer therapeutics and mechanisms
- Mechanical Circulatory Support Devices
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Neuroendocrine Tumor Research Advances
- Cardiac Arrest and Resuscitation
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
- Pancreatic and Hepatic Oncology Research
- Respiratory Support and Mechanisms
- Chemotherapy-related skin toxicity
- Cancer Research and Treatments
- Liver physiology and pathology
Kite (United States)
2023-2024
Moffitt Cancer Center
2021-2023
The University of Texas MD Anderson Cancer Center
2023
Stanford University
2021
Dana-Farber Cancer Institute
2021
Memorial Sloan Kettering Cancer Center
2021
Amgen (Switzerland)
2006-2018
Amgen (United States)
2015
Antwerp University Hospital
2006
University Hospitals of Leicester NHS Trust
2002-2003
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt first-line chemoimmunotherapy is poor.In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, that was to had no more than 12 months receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) standard care (two three cycles investigator-selected, protocol-defined chemoimmunotherapy, followed by high-dose chemotherapy...
In an analysis of the primary outcome this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those standard care. Data were needed on longer-term outcomes. Download a PDF Research Summary. we randomly assigned in 1:1 ratio to receive either axi-cel care (two three cycles...
Abstract The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T therapy (axicabtagene ciloleucel (axi-cel)) over standard care (SOC; salvage chemotherapy followed by hematopoietic transplantation) ( NCT03391466 ). Here, we present a prespecified exploratory analysis examining the association between pretreatment tumor characteristics and efficacy axi-cel versus SOC. gene expression signature (GES) CD19 associated significantly with improved...
MET gene amplification is associated with poor prognosis in gastric/gastroesophageal junction/esophageal (G/GEJ/E) cancers. We determined antitumor activity, safety, and pharmacokinetics of the small-molecule inhibitor AMG 337 MET-amplified G/GEJ/E adenocarcinoma or other solid tumors.Patients Methods: In this phase II, single-arm study, adults (cohort 1) tumors 2) received 300 mg/day orally 28-day cycles. The primary endpoint was objective response rate (ORR; cohort 1). Secondary endpoints...
Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography, a measure of burden, is promising prognostic indicator in large B-cell lymphoma (LBCL). This exploratory analysis evaluated relationships between baseline MTV (categorized as low [median or less] vs high [greater than median]) and clinical outcomes the phase 3 ZUMA-7 study (NCT03391466). Patients with LBCL relapsed within 12 months refractory to first-line chemoimmunotherapy were...
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, product apheresis attributes associated with outcomes among patients relapsed/refractory large B-cell lymphoma (LBCL) treated axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion clinical response toxicity, but not durability. In material final product, naive phenotype (CCR7+CD45RA+) expressing CD27 CD28 improved...
The optimal management of patients with relapsed/refractory large B-cell lymphoma (LBCL) after disease progression or lack response to second-line (2L) therapy remains unclear. Here, we report outcomes among who received subsequent antilymphoma per investigator discretion separately by their randomized 2L arm in ZUMA-7, namely axicabtagene ciloleucel (axi-cel) vs standard care (SOC). Progression-free survival (PFS) and overall (OS) were calculated from 3L initiation. In the SOC arm, 127 179...
Abstract Background Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) safety carfilzomib patients with progressive advanced malignancies varying degrees impaired hepatic function. Methods Patients normal function (normal) impairment (mild, moderate, severe) received infusion 28-day cycles. The primary objective was to assess influence on PK following 27 56 mg/m 2 doses. Results...
Capecitabine, a tumor-selective, oral fluoropyrimidine, has demonstrated significant antitumor activity in patients with metastatic breast cancer. In this open-label monocenter phase II study the efficacy and safety of capecitabine cancer who relapsed after high-dose chemotherapy was examined. Female 18-65 years age, histologically confirmed diagnosis cancer, (adjuvant and/or metastatic) followed by autologous peripheral blood stem cell transplantation (PBSCT) had been treated their course...
8612 Background: Patients (pts) with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) that can effectively treat CIA when administered once every 3 weeks (Q3W). In patients CIA, limited data in the literature suggest administration intravenous (IV) iron ESA therapy may increase clinical response. Methods: This randomized, multicenter, open-label, 16-week study evaluated...
A 34-yr-old male suffered multiple trauma in a road traffic accident. He required right thoracotomy and laparotomy to control exanguinating haemorrhage, received 93 u blood products. Intraoperatively, he developed severe systemic inflammatory response syndrome (SIRS) with coagulopathy respiratory failure. At the end of procedure, mean arterial pressure (MAP) was 40 mm Hg, gas analysis showed pH 6.9, Pa(CO(2)) 12 kPa, Pa(O(2)) 4.5 his core temperature 29 degrees C. There established...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The nearly 40% of patients with large B-cell (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) DA-EPOCH-R (dose-adjusted etoposide [DA-E]), have poor prognoses. High International Prognostic Index (IPI) score the subtype high-grade associated shorter progression-free...
<p>Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.</p><p>Supplementary 2. ongoing in secondline LBCL.</p><p>Supplementary 3. Early expansion correlated response.</p><p>Supplementary 4. Naive T cells associated improved outcome.</p><p>Supplementary 5. Association between toxicity and central memory product phenotype.</p><p>Supplementary 6. phenotypes/subpopulations Tcell 7. enriched...
<div>Abstract<p>Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, product apheresis attributes associated with outcomes among patients relapsed/refractory large B-cell lymphoma (LBCL) treated axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion clinical response toxicity, but not durability. In material final product, naive phenotype...
<p>Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.</p><p>Supplementary 2. ongoing in secondline LBCL.</p><p>Supplementary 3. Early expansion correlated response.</p><p>Supplementary 4. Naive T cells associated improved outcome.</p><p>Supplementary 5. Association between toxicity and central memory product phenotype.</p><p>Supplementary 6. phenotypes/subpopulations Tcell 7. enriched...
<div>Abstract<p>Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, product apheresis attributes associated with outcomes among patients relapsed/refractory large B-cell lymphoma (LBCL) treated axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion clinical response toxicity, but not durability. In material final product, naive phenotype...
<p>Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.</p><p>Supplementary 2. ongoing in secondline LBCL.</p><p>Supplementary 3. Early expansion correlated response.</p><p>Supplementary 4. Naive T cells associated improved outcome.</p><p>Supplementary 5. Association between toxicity and central memory product phenotype.</p><p>Supplementary 6. phenotypes/subpopulations Tcell 7. enriched...
<p>Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.</p><p>Supplementary 2. ongoing in secondline LBCL.</p><p>Supplementary 3. Early expansion correlated response.</p><p>Supplementary 4. Naive T cells associated improved outcome.</p><p>Supplementary 5. Association between toxicity and central memory product phenotype.</p><p>Supplementary 6. phenotypes/subpopulations Tcell 7. enriched...
A 34-yr-old male suffered multiple trauma in a road traffic accident. He required right thoracotomy and laparotomy to control exanguinating haemorrhage, received 93 u blood products. Intraoperatively, he developed severe systemic inflammatory response syndrome (SIRS) with coagulopathy respiratory failure. At the end of procedure, mean arterial pressure (MAP) was 40 mm Hg, gas analysis showed pH 6.9, PaCO2 12 kPa, PaO2 4.5 his core temperature 29°C. There established disseminated...